Predicting the Immune Response Following Intravesical BCG; is it Possible?
Author(s): Mohamed Yehia and Omar ElgebalyMohamed Yehia and Omar Elgebaly
Objective: To demonstrate and quantify the immune response changes over time in patients with Non-muscleinvasive Bladder Cancer (NMIBC) treated with bacillus Calmette-Guerin (BCG).Methods: The study enrolled 52 patients. Group A included 32 patients with high risk and intermediate risk NMIBC treated with TURBT and intravesical BCG. Group B included 20 patients underwent cystoscopy for other indications. Monitoring immune changes was done by quantifying the percentage of T lymphocytes in urine samples taken before BCG therapy, immediately after BCG therapy and 3 months later. Patients in Group A were followed for 1 year and the clinical outcome was correlated to the level of the immune response.Results: In the initial urine samples taken before BCG therapy the mean flowcytometeric percentages of the T lymphocytes were compa.. Read More»